CN103608020B - 核苷化合物在制备用于治疗登革热的药物中的用途 - Google Patents

核苷化合物在制备用于治疗登革热的药物中的用途 Download PDF

Info

Publication number
CN103608020B
CN103608020B CN201280029465.9A CN201280029465A CN103608020B CN 103608020 B CN103608020 B CN 103608020B CN 201280029465 A CN201280029465 A CN 201280029465A CN 103608020 B CN103608020 B CN 103608020B
Authority
CN
China
Prior art keywords
alkyl
benzyl
acid
dengue
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280029465.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103608020A (zh
Inventor
H·贾万巴赫特
K·克隆普
S·任
Z·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Libo Science Co Ltd
Original Assignee
Libo Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46229500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103608020(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Libo Science Co Ltd filed Critical Libo Science Co Ltd
Publication of CN103608020A publication Critical patent/CN103608020A/zh
Application granted granted Critical
Publication of CN103608020B publication Critical patent/CN103608020B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CN201280029465.9A 2011-06-10 2012-06-07 核苷化合物在制备用于治疗登革热的药物中的用途 Expired - Fee Related CN103608020B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495472P 2011-06-10 2011-06-10
US61/495,472 2011-06-10
PCT/EP2012/060781 WO2012168348A1 (en) 2011-06-10 2012-06-07 Method of treating dengue fever

Publications (2)

Publication Number Publication Date
CN103608020A CN103608020A (zh) 2014-02-26
CN103608020B true CN103608020B (zh) 2016-11-23

Family

ID=46229500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280029465.9A Expired - Fee Related CN103608020B (zh) 2011-06-10 2012-06-07 核苷化合物在制备用于治疗登革热的药物中的用途

Country Status (16)

Country Link
US (2) US20130018011A1 (https=)
EP (1) EP2717881A1 (https=)
JP (1) JP6072016B2 (https=)
KR (1) KR20140041706A (https=)
CN (1) CN103608020B (https=)
CA (1) CA2837242A1 (https=)
CL (1) CL2013003487A1 (https=)
CO (1) CO6811865A2 (https=)
CR (1) CR20130610A (https=)
EC (1) ECSP13013075A (https=)
MX (1) MX2013014389A (https=)
MY (1) MY173636A (https=)
PE (1) PE20141263A1 (https=)
PH (1) PH12013502424A1 (https=)
RU (1) RU2605904C2 (https=)
WO (1) WO2012168348A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130018011A1 (en) * 2011-06-10 2013-01-17 Hassan Javanbakht Method of treating dengue fever
WO2015158913A1 (en) * 2014-04-17 2015-10-22 Katholieke Universiteit Leuven Novel antiviral and antitumoral compounds
MX381291B (es) * 2014-09-26 2025-03-12 Riboscience Llc Derivados de nucleósidos sustituidos con 4'-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
CN106132972B (zh) * 2015-02-06 2018-08-31 银杏树药业(苏州)有限公司 用于治疗hcv感染的氨基磷酸酯
US20170232031A1 (en) * 2016-02-16 2017-08-17 Riboscience Llc Inhibitors of Zika Virus
US20180098828A1 (en) 2016-10-07 2018-04-12 3M Innovative Properties Company Ceramic dental restorations made by additive manufacturing
TWI794742B (zh) * 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042988A1 (en) * 2005-08-15 2007-02-22 Roche Palo Alto Llc Antiviral phosphoramidates
EP2166016A1 (en) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
WO2011039221A2 (en) * 2009-09-29 2011-04-07 Centocor Ortho Biotech Products L.P. Phosphoramidate derivatives of nucleosides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345657A1 (en) * 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PT2376088T (pt) * 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
EP2619215B1 (en) * 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US20130018011A1 (en) * 2011-06-10 2013-01-17 Hassan Javanbakht Method of treating dengue fever

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042988A1 (en) * 2005-08-15 2007-02-22 Roche Palo Alto Llc Antiviral phosphoramidates
EP2166016A1 (en) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
WO2011039221A2 (en) * 2009-09-29 2011-04-07 Centocor Ortho Biotech Products L.P. Phosphoramidate derivatives of nucleosides

Also Published As

Publication number Publication date
ECSP13013075A (es) 2014-01-31
JP6072016B2 (ja) 2017-02-01
CL2013003487A1 (es) 2014-09-05
PH12013502424A1 (en) 2014-01-13
RU2013156939A (ru) 2015-07-20
JP2014519507A (ja) 2014-08-14
CR20130610A (es) 2014-02-18
CN103608020A (zh) 2014-02-26
KR20140041706A (ko) 2014-04-04
PE20141263A1 (es) 2014-09-29
US20160168186A1 (en) 2016-06-16
EP2717881A1 (en) 2014-04-16
CO6811865A2 (es) 2013-12-16
MY173636A (en) 2020-02-12
RU2605904C2 (ru) 2016-12-27
MX2013014389A (es) 2014-03-21
US20130018011A1 (en) 2013-01-17
WO2012168348A1 (en) 2012-12-13
CA2837242A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CN103608020B (zh) 核苷化合物在制备用于治疗登革热的药物中的用途
CA2727495C (en) Nucleoside cyclicphosphates
KR100828453B1 (ko) Ｒｎａ 의존성 ｒｎａ 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
US9408863B2 (en) 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
CN111542531A (zh) 取代的核苷、核苷酸以及它们的类似物
IL217228A (en) Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds
CA2818853A1 (en) 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
TW201209051A (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
TW201141488A (en) Antiviral nucleosides
JP2014520822A (ja) Ｃ型肝炎ウイルス阻害剤としてのスピロ化合物
JP2014518858A (ja) Ｃ型肝炎ウイルス阻害剤
CN119212987A (zh) 用于靶向pd-l1的方法和组合物
CN112010916B (zh) 核苷化合物的氨基磷酸酯衍生物及其用途
CN112062800B (zh) 核苷化合物的氨基磷酸酯衍生物及其用途
EP2900656B1 (en) Spiro ring compounds as hepatitis c virus (hcv) inhibitors
CN106883280A (zh) 一种前药、其制备方法、药物组合物及其用途
US20170232031A1 (en) Inhibitors of Zika Virus
JP2016525114A (ja) Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ
HK1194998B (en) The use of nucleoside compounds for the preparation of a medicament for the treatment of dengue fever
HK1194998A (en) The use of nucleoside compounds for the preparation of a medicament for the treatment of dengue fever
JP2016527232A (ja) Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
KR20260016917A (ko) 항바이러스제로서의 4'-치환 뉴클레오사이드 및 뉴클레오타이드
JP2016515105A (ja) Ｃ型肝炎の処置のためのピリミジン化合物
HK1159640A (en) Nucleoside cyclicphosphates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194998

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: LIBO SCIENCE CO., LTD.

Free format text: FORMER OWNER: F. HOFFMANN-LA ROCHE AG

Effective date: 20141031

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141031

Address after: American California

Applicant after: Libo Science Co., Ltd.

Address before: Basel

Applicant before: F. Hoffmann-La Roche AG

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1194998

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161123

Termination date: 20190607

CF01 Termination of patent right due to non-payment of annual fee